Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
Idorsia Ltd (IDIA.SW) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | 23.04 M | 1.2 B | 1.66 B | 566.33 M | 312.94 M |
| 2022 | 55.9 M | 1.22 B | 1.77 B | 1.02 B | 675.57 M |
| 2021 | 1.2 B | 1.56 B | 1.68 B | 1.22 B | |
| 2020 | 563.14 M | 962.64 M | 1.63 B | 1.17 B | |
| 2019 | 417.18 M | 951.28 M | 1.14 B | 878.27 M |